Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome
Table 1
Mean age and laboratory data of the study groups.
Parameters
HRS group ()
Stable cirrhosis group ()
Control subjects ()
value
Age (years)
56.76 ± 11.66
49.06 ± 13.05
51.02 ± 10.24
<0.05
AST (U/L)
141.85 ± 32.57
56.88 ± 9.03
26.88 ± 3.65
<0.001
ALT (U/L)
87.69 ± 20.93
52.17 ± 8.82
30.24 ± 2.93
<0.001
Albumin (g/dL)
2.47 ± 0.18
3.22 ± 0.14
4.23 ± 0.20
<0.001
INR
1.79 ± 0.19
1.27 ± 0.17
0.93 ± 0.05
<0.001
Total bilirubin (mg/dL)
6.57 ± 1.96
2.84 ± 0.81
0.84 ± 0.08
<0.001
eGFR (mL/min/1.73 m2)
31.69 ± 4.93
90.92 ± 3.37
99.18 ± 0.96
<0.001
Creatinine (mg/dL)
2.11 ± 0.18
0.75 ± 0.08
0.74 ± 0.12
<0.001
MELD score
26.35 ± 1.91
13.06 ± 1.76
—
<0.001
HRS, hepatorenal syndrome; AST, aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease. Quantitative values are expressed as median ± standard deviation. versus control group, versus stable cirrhosis group, and versus HRS group.
